The most significant advance in the medical management of HIV-1 infection has been the
treatment of patients with antiviral drugs, which can suppress HIV-1 replication to …

The worldwide infection rate for HIV-1 is estimated to be 14,000 per day, but only now, more
than 20 years into the epidemic, are the immediate events between exposure to infectious …

Topical agents, such as microbicides, that can protect against human immunodeficiency
virus (HIV) transmission are urgently needed. Using a chimeric simian/human …

The main (M) group of human immunodeficiency virus type 1 (HIV-1) is responsible for the
global AIDS epidemic while HIV-1 group O (outlier) and HIV type 2 are endemic only in west …

ABSTRACT CCR5 serves as a requisite fusion coreceptor for clinically relevant strains of
human immunodeficiency virus type 1 (HIV-1) and provides a promising target for antiviral …

This study was designed to examine the impact of human immunodeficiency virus type 1
(HIV-1) fitness on disease progression through the use of a dual competition/heteroduplex …

The quinoline-based allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are promising
candidates for clinically useful antiviral agents. Studies using these compounds have …

Continual human immunodeficiency virus type 1 (HIV-1) evolution and expansion within the
human population have led to unequal distribution of HIV-1 group M subtypes. In particular …

One to two million people worldwide are infected with the human immunodeficiency virus
type 2 (HIV-2), with highest prevalences in West African countries, but also present in …

This study examined the relationship between ex vivo human immunodeficiency virus type 1
(HIV-1) fitness and viral genetic diversity during the course of HIV-1 disease. Primary HIV-1 …